Showing 761 - 780 results of 111,838 for search '(( 10 ((ng decrease) OR (we decrease)) ) OR ( 50 ((n decrease) OR (a decrease)) ))', query time: 1.24s Refine Results
  1. 761
  2. 762
  3. 763
  4. 764
  5. 765
  6. 766
  7. 767
  8. 768
  9. 769
  10. 770

    ΔAMP null mutants exhibit decreased climbing and increased sleep after TBI. by Bart van Alphen (12003724)

    Published 2022
    “…<p>(<b>A)</b> ΔAMP null mutants show decreased climbing 24 hours after TBI, similar to controls (<i>n</i> = 50–66) <b>(B)</b> Sleep is decreased in controls 24 hour after TBI <b>(C)</b> but is increased in ΔAMP null mutants (<i>n</i> = 56–95). *** <i>p</i> < 0.001, * <i>p</i> < 0.05 by <i>t</i> tests with Bonferroni correction. …”
  11. 771
  12. 772
  13. 773
  14. 774
  15. 775
  16. 776

    GBE did not modify cell morphology but decreased reactive oxygen species (ROS) levels. by Virginie Rhein (243241)

    Published 2010
    “…<b>C</b>) Mitochondria-associated ROS levels measured after incubation with DHR (DHR fluorescence units/1×10<sup>5</sup> cells). ROS levels showed a trend to be increased in APP cells compared to control cells (<sup>(</sup>*<sup>)</sup>p = 0.082, unpaired student's t-test, n = 11, values represent the means ± S.E.). …”
  17. 777

    2-CDA decreases PIN 1 protein levels in 7WD10 cells. by Crystal D. Hayes (304487)

    Published 2013
    “…(B) ImageJ quantitation revealed significantly decreased PIN 1 protein levels at 0.1 mM (39%, p<0.001), at 0.5 µM (30%, p<0.001), 1.0 µM (24%, p<0.001), 5.0 µM (19%, p<0.001) and 10.0 µM (29%, p<0.001) compared to untreated control cells n = 4 in each group. *, p<0.05, **, p<0.01, vs. untreated controls.…”
  18. 778

    Image_1_Electroencephalographic Evidence for Individual Neural Inertia in Mice That Decreases With Time.JPEG by Andrzej Z. Wasilczuk (11945885)

    Published 2022
    “…EEG was measured after induction of and emergence from isoflurane administered near the EC<sub>50</sub> dose for loss of righting in genetically inbred mice on a timescale that minimizes pharmacokinetic confounds. …”
  19. 779
  20. 780